Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PMC-309 |
Synonyms | |
Therapy Description |
PMC-309 is an antibody targeting VSIR (VISTA), which potentially induces antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 5557). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PMC-309 | PMC309|PMC 309 | VSIR Antibody 6 | PMC-309 is an antibody targeting VSIR (VISTA), which potentially induces antitumor immune activity (Cancer Res (2022) 82 (12_Supplement): 5557). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05957081 | Phase I | Pembrolizumab + PMC-309 PMC-309 | Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01) | Not yet recruiting | AUS | 0 |